Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + cetylpyridinium chloride is a combination drug used primarily for the symptomatic relief of pain and minor infections in the mouth and throat. Lidocaine is an amide-type local anesthetic that works by reversibly blocking voltage-sensitive sodium channels in nerve cell membranes, thereby inhibiting pain signal transmission. Cetylpyridinium chloride is a quaternary ammonium antiseptic with broad-spectrum antimicrobial activity, particularly against gram-positive bacteria and to a lesser extent gram-negative bacteria. This combination is commonly formulated as lozenges, gels, or liquids for topical oral use to treat sore throat and minor oral infections[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + cetylpyridinium chloride.